Table 2.
Primers used in this studya
| Primer | Sequence (5′–3′) | Purpose |
|---|---|---|
| med p1 | AAGTATCGAAAAGCTACGGAATTTCT | Δmed construction |
| med p2 | CAATTCGCCCTATAGTGAGTCGTGATCAAGTCATGTTCAACTCCTTTT | Δmed construction |
| med p3 | CCAGCTTTTGTTCCCTTTAGTGAGAACGAGTAATGGAGTGACGTCACA | Δmed construction |
| med p4 | TTTCTTCGCGCCGAGTTGTTCTT | Δmed construction |
| kinD p1 | TCTTCTTGTGATTAACCCGCCAAGA | ΔkinD construction |
| kinD p2 | CAATTCGCCCTATAGTGAGTCGTTAGTATTTTCAATTTGCATCGCTCCAA | ΔkinD construction |
| kinD p3 | CCAGCTTTTGTTCCCTTTAGTGAGTTCATATTGAAAGTGAAGTGCGAAGA | ΔkinD construction |
| kinD p4 | TGTTTAAGATATTCTTCACCTGGGTA | ΔkinD construction |
| AVB007 | GCATGTCGACTAAGGAGGTTTATAGATGATCACAAGGCTTGTCATGATCT | Phyperspank-med construction |
| AVB008 | GCATGCTAGCTTACTCGTTTTTTGGCAGCTCGC | Phyperspank-med construction |
| AVB176 | GCATAAGCTTTAAGGAGGATTTATAGATGTTGGAGCGATGCAAATTGAAAT | PxylA-kinD* construction |
| AVB177 | CGTAGCATGCTTACGTCCCGATCAGCTCTAATTTTTG | PxylA-kinD* construction |
a
Restriction endonuclease sites are underlined.